Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | qIP-MS in high-risk myeloma patients in the GEM-CESAR trial

Noemí Puig • 23 Jun 2020
EHA 2020
Multiple Myeloma Rare Diseases Smoldering Myeloma Carfilzomib Dexamethasone Lenalidomide Melphalan
GEM-CESAR

Noemí Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, discusses the use of quantitative immunoprecipitation mass spectrometry (QIP-MS) as a measure of minimal residual disease (MRD) in high-risk smoldering myeloma patients enrolled in the GEM-CESAR study (NCT02415413). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Noemí Puig

Methods for using mass spectrometry in the PB versus MRD in the bone marrow in multiple myeloma 2:17
Methods for using mass spectrometry in the PB versus MRD in the bone marrow in multiple myeloma
Noemí Puig • 18 Sep 2025
Evidence supporting the use of MRD-guided treatment in multiple myeloma: GEM2014MAIN and AURIGA 3:49
Evidence supporting the use of MRD-guided treatment in multiple myeloma: GEM2014MAIN and AURIGA
Noemí Puig • 18 Sep 2025
Investigating the use of mass spectrometry & NGF to measure MRD and predict outcomes in HR-SMM 2:20
Investigating the use of mass spectrometry & NGF to measure MRD and predict outcomes in HR-SMM
Noemí Puig • 7 Oct 2024
The value of mass spectrometry in multiple myeloma & how this may impact clinical practice 1:49
The value of mass spectrometry in multiple myeloma & how this may impact clinical practice
Noemí Puig • 7 Oct 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals